{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:29:07Z","timestamp":1780666147909,"version":"3.54.1"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Acute lymphoblastic leukemia (ALL) constitutes 20% to 30% of all pediatric cancers. The 5-year overall survival among pediatric patients with ALL in high-income countries such as Sweden is currently more than 90%, but long-term unselected nationwide mortality data and mortality data in relation to the general population are lacking.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare mortality between pediatric patients with ALL and the general population during a 30-year period in Sweden and to assess the incidence of ALL in Sweden.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study included pediatric patients (aged &amp;lt;18 years) with a morphologically verified ALL diagnosis in the Swedish Cancer Register and\/or at least 2 ALL diagnoses in the Swedish National Patient Register between January 1, 1988, and December 31, 2017. Data were cross-linked to the Swedish Cause of Death Register. Data were analyzed from May 2019 to January 2022.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcomes were mortality among patients with ALL compared with that in the general population and mortality in different subgroups within the cohort. Standardized mortality ratios (SMRs) were calculated using the general Swedish population as a reference. Within-cohort survival analyses were performed.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 2397 patients (1354 [56%] male; mean [SD] age at diagnosis, 6.1 [4.7] years) were included in the study. The mean (SD) incidence of pediatric ALL during the study period was 4.11 (0.60) cases per 100 000 persons per year (females, 3.68 [0.65] cases per 100 000 persons per year; males, 4.52 [0.81] cases per 100 000 persons per year; P<\/jats:italic>\u2009&amp;lt;\u2009.001). The observed number of deaths among pediatric patients with ALL was 409 vs the 9.5 deaths expected in the general population, resulting in an overall SMR of 43.1 (95% CI, 39.0-47.5); females had a higher SMR than males (57.8 [95% CI, 49.5-67.2] vs 34.5 [95% CI, 32.0-41.4]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Analysis within the cohort showed a continued decrease in survival throughout the 30-year follow-up. The association between calendar year of ALL diagnosis, corresponding with different ALL treatment protocols, and mortality showed the lowest survival for the 1988-1991 group and the highest for the 2008-2017 group (\u03c72<\/jats:sup>\u2009=\u200920.3; P<\/jats:italic>\u2009&amp;lt;\u2009.001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, a consistently high SMR was seen among pediatric patients with ALL. Within the ALL cohort, survival evolved to a similar extent as in the young general population of Sweden. Furthermore, survival among patients with ALL decreased throughout the whole follow-up period without any trend difference after the 5-year follow-up time point. The changes in ALL treatment protocols were associated with overall improved absolute survival over time.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.43857","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T16:33:40Z","timestamp":1669653220000},"page":"e2243857","source":"Crossref","is-referenced-by-count":15,"title":["Mortality Among Pediatric Patients With Acute Lymphoblastic Leukemia in Sweden From 1988 to 2017"],"prefix":"10.1001","volume":"5","author":[{"given":"Thomas","family":"Bj\u00f6rk-Eriksson","sequence":"first","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Regional Cancer Centre West, Western Sweden Healthcare Region, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bostr\u00f6m","sequence":"additional","affiliation":[{"name":"Medical Affairs, Neurology, Go North Medical AB, Gothenburg, Sweden"},{"name":"Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ing-Liss","family":"Bryngelsson","sequence":"additional","affiliation":[{"name":"Department of Occupational and Environmental Medicine, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi M.","family":"L\u00e4hteenm\u00e4ki","sequence":"additional","affiliation":[{"name":"Swedish Childhood Cancer Registry, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Jarfelt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Oncology at Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kalm","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Olsson","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"},{"name":"Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Endocrinology at Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"36","key":"zoi221234r1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.15585\/mmwr.mm6636a3","article-title":"Rates and trends of pediatric acute lymphoblastic leukemia\u2014United States, 2001-2014.","volume":"66","author":"Siegel","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"zoi221234r3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children.","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"10230","key":"zoi221234r4","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia.","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"zoi221234r5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1542\/peds.50.2.246","article-title":"Nine years\u2019 experience with \u201ctotal therapy\u201d of childhood acute lymphocytic leukemia.","volume":"50","author":"Pinkel","year":"1972","journal-title":"Pediatrics"},{"issue":"11","key":"zoi221234r6","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia.","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"zoi221234r7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia.","volume":"107","author":"Gurney","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"zoi221234r8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.2009.22.5060","article-title":"Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.","volume":"28","author":"Goldsby","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi221234r9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/apa.1981.70.issue-1","article-title":"Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia in Norway. Preliminary results of a national treatment program.","volume":"70","author":"Moe","year":"1981","journal-title":"Acta Paediatr Scand"},{"issue":"7","key":"zoi221234r10","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1200\/JCO.2003.04.039","article-title":"Intensification of mercaptopurine\/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.","volume":"21","author":"Schmiegelow","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi221234r11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/leu.2009.251","article-title":"Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.","volume":"24","author":"Schmiegelow","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"zoi221234r12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"14","key":"zoi221234r13","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2008.21.1425","article-title":"Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study.","volume":"27","author":"Armstrong","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi221234r14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(14)70265-7","article-title":"Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort.","volume":"15","author":"Essig","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi221234r15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1056\/NEJMoa1510795","article-title":"Reduction in late mortality among 5-year survivors of childhood cancer.","volume":"374","author":"Armstrong","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi221234r16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jama.2010.923","article-title":"Long-term cause-specific mortality among survivors of childhood cancer.","volume":"304","author":"Reulen","year":"2010","journal-title":"JAMA"},{"issue":"7","key":"zoi221234r17","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/ijc.v131.7","article-title":"Late and very late mortality in 5-year survivors of childhood cancer: changing pattern over four decades\u2014experience from the Nordic countries.","volume":"131","author":"Garwicz","year":"2012","journal-title":"Int J Cancer"},{"issue":"11","key":"zoi221234r18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"zoi221234r19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1054\/bjoc.2001.1868","article-title":"Excess breast cancer risk and the role of parity, age at first childbirth and exposure to radiation in infancy.","volume":"85","author":"Holmberg","year":"2001","journal-title":"Br J Cancer"},{"issue":"1","key":"zoi221234r20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998.","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"issue":"9","key":"zoi221234r21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register.","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"zoi221234r24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register.","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"7382","key":"zoi221234r25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates.","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"issue":"26","key":"zoi221234r26","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation.","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi221234r27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/apa.2019.108.issue-1","article-title":"Childhood death rates declined in Sweden from 2000 to 2014 but deaths from external causes were not always investigated.","volume":"108","author":"Otterman","year":"2019","journal-title":"Acta Paediatr"},{"issue":"1","key":"zoi221234r28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3324\/haematol.2015.131680","article-title":"Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.","volume":"101","author":"Oskarsson","year":"2016","journal-title":"Haematologica"},{"key":"zoi221234r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101768","article-title":"Childhood cancer mortality trends in Europe, 1990-2017, with focus on geographic differences.","volume":"67","author":"Bertuccio","year":"2020","journal-title":"Cancer Epidemiol"},{"issue":"9947","key":"zoi221234r30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(14)60497-9","article-title":"Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.","volume":"384","author":"Wang","year":"2014","journal-title":"Lancet"},{"key":"zoi221234r31","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/865979","article-title":"Characterization of pediatric acute lymphoblastic leukemia survival patterns by age at diagnosis.","volume":"2014","author":"Hossain","year":"2014","journal-title":"J Cancer Epidemiol"},{"issue":"2","key":"zoi221234r32","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz032","article-title":"Survival differences between males and females diagnosed with childhood cancer.","volume":"3","author":"Williams","year":"2019","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"1","key":"zoi221234r33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","article-title":"Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5\u2014a population-based study.","volume":"15","author":"Gatta","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi221234r34","first-page":"243","article-title":"Sex and other prognostic factors in acute lymphoblastic leukemia in childhood.","volume":"5","author":"Gustafsson","year":"1983","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"1","key":"zoi221234r35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/apa.1992.81.issue-1","article-title":"Superior treatment results in females with high-risk acute lymphoblastic leukemia in childhood.","volume":"81","author":"Lanning","year":"1992","journal-title":"Acta Paediatr"},{"issue":"12","key":"zoi221234r36","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1002\/pbc.25628","article-title":"Comparative toxicity by sex among children treated for acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group.","volume":"62","author":"Meeske","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"zoi221234r37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/adc.74.2.101","article-title":"Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.","volume":"74","author":"Wheeler","year":"1996","journal-title":"Arch Dis Child"},{"issue":"4","key":"zoi221234r38","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v65.4","article-title":"Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia.","volume":"65","author":"Oskarsson","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"zoi221234r39","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s41416-019-0632-1","article-title":"Survival after cancer in children, adolescents and young adults in the Nordic countries from 1980 to 2013.","volume":"121","author":"Rostgaard","year":"2019","journal-title":"Br J Cancer"},{"key":"zoi221234r2","unstructured":"\u00c5rsrapport 2020 Svenska Barncancerregistret. Accessed August 31, 2021. https:\/\/cceg.ki.se\/documents\/Arsrapport_SBCR_2020.pdf"},{"key":"zoi221234r22","unstructured":"Johansson? LA. 2010. D\u00f6dsorsaksstatistik: historik, produktionsmetoder och tillf\u00f6rlitlighet. The National Board of Health and Welfare. Accessed March 12, 2022. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/statistik\/2010-4-33.pdf"},{"key":"zoi221234r23","unstructured":"Official Statistics of Sweden\u2014Health and Diseases. Cancer incidence in Sweden 2011. Centre for Epidemiology. National Board of Health and Welfare. Accessed March 12, 2022. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/statistik\/2012-12-19.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2799016\/bjrkeriksson_2022_oi_221234_1668781347.52451.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T16:33:45Z","timestamp":1669653225000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2799016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.43857","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]}}}